Nolato: Continued challenges - ABG

EBITA SEK 214m (-8% vs. cons. 232m)
Consensus ’23e-’24e EBITA likely down by ~1-2%
Trading at 11x ’23e EV/EBITA on pre-Q3 numbers


Q3 outcome

Sales were SEK 2,626m (+4% vs. ABGSCe 2,537m, +3% vs. FactSet cons 2,557m), down 13% y-o-y, of which -24% organic (ABGSCe -26%). EBITA came in at SEK 214m (-7% vs ABGSCe 230m, -8% vs. cons 232m), for an EBITA margin 8.1% (ABGSCe 9.1%, cons 9.1%), and this included no NRIs (ABGSCe 0m, cons. 0m). Net profit was SEK 160m (-3% vs. ABGSCe 164m, -4% vs. cons. 167m). The softer margins were a result of continued lag on moving on input costs, lower volumes leading to irregular capacity utilisation, and an unfavourable sales mix in Medical.

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/nolato/Equity-research/2022/10/nolato---continued-challenges/